Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.342
Filtrer
1.
Biomolecules ; 14(6)2024 Jun 19.
Article de Anglais | MEDLINE | ID: mdl-38927131

RÉSUMÉ

Peroxisome proliferator-activated receptor gamma (PPARγ) is a transcription factor expressed in many tissues, including skin, where it is essential for maintaining skin barrier permeability, regulating cell proliferation/differentiation, and modulating antioxidant and inflammatory responses upon ligand binding. Therefore, PPARγ activation has important implications for skin homeostasis. Over the past 20 years, with increasing interest in the role of PPARs in skin physiopathology, considerable effort has been devoted to the development of PPARγ ligands as a therapeutic option for skin inflammatory disorders. In addition, PPARγ also regulates sebocyte differentiation and lipid production, making it a potential target for inflammatory sebaceous disorders such as acne. A large number of studies suggest that PPARγ also acts as a skin tumor suppressor in both melanoma and non-melanoma skin cancers, but its role in tumorigenesis remains controversial. In this review, we have summarized the current state of research into the role of PPARγ in skin health and disease and how this may provide a starting point for the development of more potent and selective PPARγ ligands with a low toxicity profile, thereby reducing unwanted side effects.


Sujet(s)
Récepteur PPAR gamma , Peau , Récepteur PPAR gamma/métabolisme , Humains , Animaux , Peau/métabolisme , Peau/anatomopathologie , Tumeurs cutanées/métabolisme , Tumeurs cutanées/anatomopathologie , Maladies de la peau/métabolisme , Maladies de la peau/anatomopathologie , Ligands , Différenciation cellulaire
2.
Exp Dermatol ; 33(6): e15114, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38853773

RÉSUMÉ

Ferroptosis is a novel type of cell death that is dependent on lipid peroxidation and iron accumulation, which distinguishes it from other types of programmed cell death. Current research indicates a significant association between ferroptosis and various pathological conditions, including cancer, neurological disorders, and cardiovascular diseases, albeit with a relatively unexplored role in dermatological afflictions. This paper elaborates on the mechanisms and signalling pathways of ferroptosis, summarizing the recent studies on ferroptosis and its related factors in dermatosis. Our objective is to shed light on novel perspectives and therapeutic strategies for dermatosis, enhancing the understanding of this under-researched area through this comprehensive review.


Sujet(s)
Ferroptose , Transduction du signal , Maladies de la peau , Ferroptose/physiologie , Humains , Maladies de la peau/métabolisme , Fer/métabolisme , Peroxydation lipidique , Animaux
3.
Int J Mol Sci ; 25(11)2024 May 27.
Article de Anglais | MEDLINE | ID: mdl-38891997

RÉSUMÉ

Inflammatory skin diseases highlight inflammation as a central driver of skin pathologies, involving a multiplicity of mediators and cell types, including immune and non-immune cells. Adenosine, a ubiquitous endogenous immune modulator, generated from adenosine triphosphate (ATP), acts via four G protein-coupled receptors (A1, A2A, A2B, and A3). Given the widespread expression of those receptors and their regulatory effects on multiple immune signaling pathways, targeting adenosine receptors emerges as a compelling strategy for anti-inflammatory intervention. Animal models of psoriasis, contact hypersensitivity (CHS), and other dermatitis have elucidated the involvement of adenosine receptors in the pathogenesis of these conditions. Targeting adenosine receptors is effective in attenuating inflammation and remodeling the epidermal structure, potentially showing synergistic effects with fewer adverse effects when combined with conventional therapies. What is noteworthy are the promising outcomes observed with A2A agonists in animal models and ongoing clinical trials investigating A3 agonists, underscoring a potential therapeutic approach for the management of inflammatory skin disorders.


Sujet(s)
Adénosine , Récepteurs purinergiques P1 , Humains , Animaux , Adénosine/métabolisme , Récepteurs purinergiques P1/métabolisme , Maladies de la peau/traitement médicamenteux , Maladies de la peau/métabolisme , Dermatite/métabolisme , Dermatite/traitement médicamenteux , Dermatite/anatomopathologie , Dermatite/étiologie , Inflammation/métabolisme , Inflammation/traitement médicamenteux , Inflammation/anatomopathologie , Psoriasis/traitement médicamenteux , Psoriasis/métabolisme , Transduction du signal , Anti-inflammatoires/usage thérapeutique
4.
Int J Mol Sci ; 25(11)2024 May 29.
Article de Anglais | MEDLINE | ID: mdl-38892115

RÉSUMÉ

Recently, the pathomechanisms of various skin diseases have been progressively elucidated [...].


Sujet(s)
Maladies de la peau , Humains , Maladies de la peau/génétique , Maladies de la peau/métabolisme
5.
Bioessays ; 46(7): e2400047, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38769699

RÉSUMÉ

Recent insights reveal the significant role of TRPV3 in warmth sensation. A novel finding elucidated how thermosensation is affected by TRPV3 membrane abundance that is modulated by the transmembrane protein TMEM79. TRPV3 is a warmth-sensitive ion channel predominantly expressed in epithelial cells, particularly skin keratinocytes. Multiple studies investigated the roles of TRPV3 in cutaneous physiology and pathophysiology. TRPV3 activation by innocuous warm temperatures in keratinocytes highlights its significance in temperature sensation, but whether TRPV3 directly contributes to warmth sensations in vivo remains controversial. This review explores the electrophysiological and structural properties of TRPV3 and how modulators affect its intricate regulatory mechanisms. Moreover, we discuss the multifaceted involvement of TRPV3 in skin physiology and pathology, including barrier formation, hair growth, inflammation, and itching. Finally, we examine the potential of TRPV3 as a therapeutic target for skin diseases and highlight its diverse role in maintaining skin homeostasis.


Sujet(s)
Homéostasie , Kératinocytes , Peau , Canaux cationiques TRPV , Canaux cationiques TRPV/métabolisme , Humains , Animaux , Peau/métabolisme , Kératinocytes/métabolisme , Thermoception/physiologie , Maladies de la peau/métabolisme , Maladies de la peau/traitement médicamenteux
6.
Exp Dermatol ; 33(5): e15084, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38711223

RÉSUMÉ

The transmembrane protein claudin-1 is critical for formation of the epidermal barrier structure called tight junctions (TJ) and has been shown to be important in multiple disease states. These include neonatal ichthyosis and sclerosing cholangitis syndrome, atopic dermatitis and various viral infections. To develop a model to investigate the role of claudin-1 in different disease settings, we used CRISPR/Cas9 to generate human immortalized keratinocyte (KC) lines lacking claudin-1 (CLDN1 KO). We then determined whether loss of claudin-1 expression affects epidermal barrier formation/function and KC differentiation/stratification. The absence of claudin-1 resulted in significantly reduced barrier function in both monolayer and organotypic cultures. CLDN1 KO cells demonstrated decreases in gene transcripts encoding the barrier protein filaggrin and the differentiation marker cytokeratin-10. Marked morphological differences were also observed in CLDN1 KO organotypic cultures including diminished stratification and reduced formation of the stratum granulosum. We also detected increased proliferative KC in the basale layer of CLDN1 KO organotypic cultures. These results further support the role of claudin-1 in epidermal barrier and suggest an additional role of this protein in appropriate stratification of the epidermis.


Sujet(s)
Différenciation cellulaire , Claudine-1 , Épiderme , Protéines filaggrine , Kératinocytes , Kératinocytes/métabolisme , Claudine-1/métabolisme , Claudine-1/génétique , Humains , Protéines filaggrine/métabolisme , Épiderme/métabolisme , Épiderme/anatomopathologie , Maladies de la peau/génétique , Maladies de la peau/métabolisme , Jonctions serrées/métabolisme , Kératine-10/métabolisme , Kératine-10/génétique , Techniques de knock-out de gènes , Prolifération cellulaire , Systèmes CRISPR-Cas
7.
Exp Dermatol ; 33(5): e15083, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38794808

RÉSUMÉ

Interferons (IFNs) are signalling proteins primarily involved in initiating innate immune responses against pathogens and promoting the maturation of immune cells. Interferon Regulatory Factor 7 (IRF7) plays a pivotal role in the IFNs signalling pathway. The activation process of IRF7 is incited by exogenous or abnormal nucleic acids, which is followed by the identification via pattern recognition receptors (PRRs) and the ensuing signalling cascades. Upon activation, IRF7 modulates the expression of both IFNs and inflammatory gene regulation. As a multifunctional transcription factor, IRF7 is mainly expressed in immune cells, yet its presence is also detected in keratinocytes, fibroblasts, and various dermal cell types. In these cells, IRF7 is critical for skin immunity, inflammation, and fibrosis. IRF7 dysregulation may lead to autoimmune and inflammatory skin conditions, including systemic scleroderma (SSc), systemic lupus erythematosus (SLE), Atopic dermatitis (AD) and Psoriasis. This comprehensive review aims to extensively elucidate the role of IRF7 and its signalling pathways in immune cells and keratinocytes, highlighting its significance in skin-related and connective tissue diseases.


Sujet(s)
Maladies du tissu conjonctif , Facteur-7 de régulation d'interféron , Kératinocytes , Transduction du signal , Maladies de la peau , Humains , Facteur-7 de régulation d'interféron/métabolisme , Facteur-7 de régulation d'interféron/génétique , Maladies de la peau/immunologie , Maladies de la peau/métabolisme , Kératinocytes/métabolisme , Kératinocytes/immunologie , Maladies du tissu conjonctif/métabolisme , Maladies du tissu conjonctif/immunologie , Psoriasis/immunologie , Psoriasis/métabolisme , Animaux , Peau/métabolisme , Peau/immunologie , Sclérodermie systémique/métabolisme , Sclérodermie systémique/immunologie , Sclérodermie systémique/génétique , Immunité innée
8.
J Cutan Pathol ; 51(7): 506-512, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38606952

RÉSUMÉ

Crystal-storing histiocytosis (CSH) is a rare condition in which crystals accumulate in the cytoplasm of histiocytes and is usually associated with a lymphoplasmacytic neoplasm. Cutaneous CSH is extraordinarily rare and limited to case reports in the literature. We report two cases of this disease with cutaneous involvement. Case 1 was a 65-year-old male with a 4-month history of a pruritic eruption that started as a solitary pink to skin-colored indurated plaque on the anterior neck before progressing to involve the whole neck, chest wall, and face. Case 2 was a 54-year-old woman with a history of unspecified "lymphoma" who presented with a soft nodule on the forearm. Biopsies from both cases had similar findings and showed a proliferation of epithelioid cells with pink cytoplasm and intracellular crystalline structures infiltrating the dermis and subcutaneous fat. In the first case, the cells were positive for CD43, CD45, CD68, and IgG kappa, and in the second case, the crystals were positive for IgG lambda. Based on these findings, the patients were diagnosed with cutaneous CSH. We highlight this rare diagnosis and the importance of investigating an underlying lymphoplasmacytic neoplasm.


Sujet(s)
Histiocytose , Humains , Sujet âgé , Mâle , Femelle , Histiocytose/anatomopathologie , Histiocytose/métabolisme , Adulte d'âge moyen , Histiocytes/anatomopathologie , Histiocytes/métabolisme , Cristallisation , Maladies de la peau/anatomopathologie , Maladies de la peau/métabolisme
9.
Article de Chinois | MEDLINE | ID: mdl-38664034

RÉSUMÉ

Skin fibrosis diseases mainly include hypertrophic scar, keloid, and systemic sclerosis, etc. The main pathological features are excessive activation of fibroblasts and abnormal deposition of extracellular matrix. In recent years, studies have shown that aerobic glycolysis is closely related to the occurrence and development of skin fibrosis diseases. Drugs targeting aerobic glycolysis has provided new ideas for skin anti-fibrosis treatment. This article reviews the role of enzymes and products related to aerobic glycolysis in the occurrence and development of skin fibrosis diseases and the drugs targeting aerobic glycolysis for the treatment of skin fibrosis diseases.


Sujet(s)
Fibrose , Glycolyse , Humains , Fibrose/métabolisme , Fibrose/anatomopathologie , Maladies de la peau/métabolisme , Maladies de la peau/anatomopathologie , Maladies de la peau/traitement médicamenteux , Peau/anatomopathologie , Peau/métabolisme , Chéloïde/métabolisme , Chéloïde/anatomopathologie , Chéloïde/traitement médicamenteux , Sclérodermie systémique/métabolisme , Sclérodermie systémique/anatomopathologie , Sclérodermie systémique/traitement médicamenteux
10.
Arch Dermatol Res ; 316(5): 123, 2024 Apr 17.
Article de Anglais | MEDLINE | ID: mdl-38630260

RÉSUMÉ

Thymic Stromal Lymphopoietin (TSLP) is an important cytokine that invokes early immune responses. TSLP, an IL-7-like cytokine encoded by the TSLP gene, activates JAK1 and JAK2 signaling pathways, stimulating dendritic cells to induce inflammatory Th2 cells. This cytokine is associated with pruritus in various cutaneous disorders, particularly atopic dermatitis. Varying levels of the cytokine TSLP have been demonstrated in studies of different cutaneous disorders. Pharmacological treatment targeting TSLP has been explored recently, particularly in the realm of atopic dermatitis.This review explores the relation of TSLP to cutaneous diseases, highlighting its potential as a biomarker for monitoring disease progression in discoid lupus erythematosus (DLE). The pharmacological therapy involving TSLP is discussed, along with the potential role of TSLP promotion in the treatment of alopecia areata. This overview examines the background, structure, and functions of TSLP, with a focus on its association with cutaneous disorders and a special focus on the impact of the atopic march.


Sujet(s)
Maladies de la peau , Lymphopoïétine stromale thymique , Humains , Pelade , Cytokines , Eczéma atopique , Maladies de la peau/métabolisme , Maladies de la peau/anatomopathologie , Lymphopoïétine stromale thymique/métabolisme
11.
Mol Med ; 30(1): 52, 2024 Apr 19.
Article de Anglais | MEDLINE | ID: mdl-38641575

RÉSUMÉ

BACKGROUND: Skin fibrosis affects the normal function of the skin. TGF-ß1 is a key cytokine that affects organ fibrosis. The latency-associated peptide (LAP) is essential for TGF-ß1 activation. We previously constructed and prepared truncated LAP (tLAP), and confirmed that tLAP inhibited liver fibrosis by affecting TGF-ß1. SPACE peptide has both transdermal and transmembrane functions. SPACE promotes the delivery of macromolecules through the stratum corneum into the dermis. This study aimed to alleviate skin fibrosis through the delivery of tLAP by SPACE. METHODS: The SPACE-tLAP (SE-tLAP) recombinant plasmid was constructed. SE-tLAP was purified by nickel affinity chromatography. The effects of SE-tLAP on the proliferation, migration, and expression of fibrosis-related and inflammatory factors were evaluated in TGF-ß1-induced NIH-3T3 cells. F127-SE-tLAP hydrogel was constructed by using F127 as a carrier to load SE-tLAP polypeptide. The degradation, drug release, and biocompatibility of F127-SE-tLAP were evaluated. Bleomycin was used to induce skin fibrosis in mice. HE, Masson, and immunohistochemistry were used to observe the skin histological characteristics. RESULTS: SE-tLAP inhibited the proliferation, migration, and expression of fibrosis-related and inflammatory factors in NIH-3T3 cells. F127-SE-tLAP significantly reduced ECM production, collagen deposition, and fibrotic pathological changes, thereby alleviating skin fibrosis. CONCLUSION: F127-SE-tLAP could increase the transdermal delivery of LAP, reduce the production and deposition of ECM, inhibit the formation of dermal collagen fibers, and alleviate the progression of skin fibrosis. It may provide a new idea for the therapy of skin fibrosis.


Sujet(s)
Polyéthylènes , Polypropylènes , Maladies de la peau , Facteur de croissance transformant bêta , Animaux , Souris , Bléomycine/effets indésirables , Collagène/métabolisme , Fibrose/traitement médicamenteux , Hydrogels/composition chimique , Hydrogels/pharmacologie , Polyéthylènes/pharmacologie , Polypropylènes/pharmacologie , Transduction du signal , Facteur de croissance transformant bêta/métabolisme , Facteur de croissance transformant bêta-1/métabolisme , Maladies de la peau/induit chimiquement , Maladies de la peau/traitement médicamenteux , Maladies de la peau/métabolisme , Protéines Smad/effets des médicaments et des substances chimiques , Protéines Smad/métabolisme , Peau/effets des médicaments et des substances chimiques , Peau/métabolisme , Peau/anatomopathologie
12.
Expert Rev Mol Med ; 26: e15, 2024 Apr 15.
Article de Anglais | MEDLINE | ID: mdl-38621674

RÉSUMÉ

In mammals, the skin acts as a barrier to prevent harmful environmental stimuli from entering the circulation. CYP450s are involved in drug biotransformation, exogenous and endogenous substrate metabolism, and maintaining the normal physiological function of the skin, as well as facilitating homeostasis of the internal environment. The expression pattern of CYP450s in the skin is tissue-specific and thus differs from the liver and other organs. The development of skin topical medications, and knowledge of the toxicity and side effects of these medications require a detailed understanding of the expression and function of skin-specific CYP450s. Thus, we summarized the expression of CYP450s in the skin, their function in endogenous metabolic physiology, aberrant CYP450 expression in skin diseases and the influence of environmental variables and medications. This information will serve as a crucial foundation for future studies on the skin, as well as for the design and development of new drugs for skin diseases including topical medications.


Sujet(s)
Cytochrome P-450 enzyme system , Peau , Humains , Peau/métabolisme , Cytochrome P-450 enzyme system/métabolisme , Cytochrome P-450 enzyme system/génétique , Animaux , Maladies de la peau/métabolisme
13.
J Ethnopharmacol ; 328: 118059, 2024 Jun 28.
Article de Anglais | MEDLINE | ID: mdl-38508430

RÉSUMÉ

ETHNOPHARMACOLOGICAL RELEVANCE: Psoriasis is characterized by hyperkeratosis that produces the classic silvery scales, and the pathogenesis of psoriasis involves abnormal proliferation of keratinocytes. Emerging evidence supports that apoptosis regulates keratinocyte proliferation and formation of stratum corneum, which maintains the homeostasis of the skin. Qinzhuliangxue mixture (QZLX) is a representative formula for the treatment of psoriasis, which was earliest recorded in the classic Chinese medicine book Xia's Surgery. In our previous clinical studies, QZLX demonstrated 83.33% efficacy with few side effects in the treatment of psoriasis. Furthermore, our published basic research has also proved that the QZLX mixture effectively inhibits the hyperproliferation of keratinocytes, thus exerting therapeutic effects on psoriasis. However, whether QZLX mixture can regulate keratinocytes apoptosis requires further clarification. OBJECTIVE OF THE STUDY: To investigate the mechanism of QZLX in the treatment of psoriasis from the perspective of keratinocyte apoptosis. MATERIALS AND METHODS: First, psoriasis-like mice with imiquimod (IMQ)-induced were given QZLX intragastric administration and Psoriasis Area Severity Index (PASI) scores were recored for 11 consecutive days to appraise the efficacy. Then, tissue samples were collected for transcriptome analysis. The DEseq2 method detected significantly differentially expressed genes (DEGs), Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway databases were used to analyze the functions and pathway enrichment of DEGs. After that, the therapeutic mechanisms of QZLX in intervening with psoriasis were explored using TUNEL, immunohistochemical staining, and western blotting. RESULTS: QZLX ameliorated the symptoms and pathological characteristics of IMQ-induced psoriasis in mice. The epidermal cell hyperplasia in the skin was inhibited, in accordance with the suppressed expression of PCNA and Ki67 after treatment. Transcriptome sequencing showed that melanoma differentiation associated gene-5 (MDA-5) was downregulated. GO and KEGG enrichment analysis of the signaling pathways indicated that the differentially expressed genes were significantly enriched in apoptosis pathways. Besides, QZLX treatment decreased the apoptosis of keratinocyte as shown by reduced TUNEL-positive cells. As MDA-5 protein levels decreased, so did the expression of the downstream protein Caspase-8, which indicates that the apoptotic pathway was triggered. Furthermore, QZLX therapy might also help to balance the apoptotic Bcl-2 family expression. CONCLUSION: QZLX restrains the apoptosis of keratinocyte in psoriasis-like mice by downregulating the MDA-5 pathway. The restoration of the balance between cell apoptosis and proliferation in the skin may lead to considerable psoriasis relief. Our study reveals the possible molecular processes behind the effects of QZLX therapy on the skin lesions of psoriasis, and lends support to its clinical efficacy.


Sujet(s)
Psoriasis , Maladies de la peau , Animaux , Souris , Psoriasis/anatomopathologie , Peau , Kératinocytes , Maladies de la peau/métabolisme , Imiquimod , Prolifération cellulaire , Hyperplasie/anatomopathologie , Apoptose , Souris de lignée BALB C , Modèles animaux de maladie humaine
14.
Skin Res Technol ; 30(3): e13655, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38481085

RÉSUMÉ

BACKGROUND: The stratum corneum (SC), the outermost layer of the skin epidermis, acts as an effective bi-directional barrier, preventing water loss (inside-outside barrier) and entry of foreign substances (outside-inside barrier). Although transepidermal water loss (TEWL) is a widely-used measure of barrier function, it represents only inside-outside protection. Therefore, we aimed to establish a non-invasive method for quantitative evaluation of the outside-inside barrier function and visually present a skin barrier model. MATERIALS AND METHODS: Skin barrier damage was induced by applying a closed patch of 1% sodium dodecyl sulfate to the forearms of eight participants; they were instructed to apply a barrier cream on a designated damaged area twice daily for 5 days. The SC barrier was evaluated by measuring TEWL and fluorescein sodium salt penetration rate before, immediately after, and 5 days after damage. The penetration rate was assessed using tape-stripping (TS) technique and fluorescence microscopy. RESULTS: The rates of fluorescein sodium salt penetration into the lower layers of SC differed significantly based on the degree of skin barrier damage. The correlation between penetration rate and TEWL was weak after two rounds of TS and became stronger after subsequent rounds. Five days after skin barrier damage, the penetration rate of all layers differed significantly between areas with and without the barrier cream application. CONCLUSION: Our findings demonstrated that the penetration rate was dependent on skin barrier conditions. The penetration rate and corresponding fluorescence images are suitable quantitative indicators that can visually represent skin barrier conditions.


Sujet(s)
Maladies de la peau , Perte insensible en eau , Humains , Fluorescéine/métabolisme , Fluorescéine/pharmacologie , Épiderme/métabolisme , Peau/métabolisme , Maladies de la peau/métabolisme , Eau/métabolisme , Émollient/pharmacologie
15.
Int J Mol Sci ; 25(4)2024 Feb 19.
Article de Anglais | MEDLINE | ID: mdl-38397118

RÉSUMÉ

Chronic and excessive ultraviolet (UVA/UVB) irradiation exposure is known as a major contributor to premature skin aging, which leads to excessive reactive oxygen species generation, disturbed extracellular matrix homeostasis, DNA damage, and chronic inflammation. Sunscreen products are the major preventive option against UVR-induced photodamage, mostly counteracting the acute skin effects and only mildly counteracting accelerated aging. Therefore, novel anti-photoaging and photopreventive compounds are a subject of increased scientific interest. Our previous investigations revealed that the endemic plant Haberlea rhodopensis Friv. (HRE) activates the antioxidant defense through an NRF2-mediated mechanism in neutrophiles. In the present study, we aimed to investigate the photoprotective potential of HRE and two of its specialized compounds-the phenylethanoid glycosides myconoside (MYC) and calceolarioside E (CAL)-in UVA/UVB-stimulated human keratinocytes in an in vitro model of photoaging. The obtained data demonstrated that the application of HRE, MYC, and CAL significantly reduced intracellular ROS formation in UVR-exposed HaCaT cells. The NRF2/PGC-1α and TGF-1ß/Smad/Wnt signaling pathways were pointed out as having a critical role in the observed CAL- and MYC-induced photoprotective effect. Collectively, CAL is worth further evaluation as a potent natural NRF2 activator and a promising photoprotective agent that leads to the prevention of UVA/UVB-induced premature skin aging.


Sujet(s)
Acides caféiques , Glucosides , Vieillissement de la peau , Maladies de la peau , Humains , Acides caféiques/pharmacologie , Facteur-2 apparenté à NF-E2/métabolisme , Espèces réactives de l'oxygène/métabolisme , Peau/métabolisme , Maladies de la peau/métabolisme , Rayons ultraviolets/effets indésirables
16.
Skin Res Technol ; 30(2): e13603, 2024 Feb.
Article de Anglais | MEDLINE | ID: mdl-38332513

RÉSUMÉ

BACKGROUND: Psoriasis is a prevalent, long-term skin condition characterized by inflammation. Keratinocytes (KCs) are important effector cells that release inflammatory factors and chemokines to promote the inflammatory cascade in psoriasis. However, the mechanisms underlying the activation of KCs in psoriasis remain unclear. Livin suppresses apoptotic proteins and directly affects the growth and spread of cancer cells. Livin expression reportedly increases significantly in lesions of patients with psoriasis; however, its specific role in KC activation remains unknown. This study aimed to examine the impact of Livin on KC activation and the subsequent release of inflammatory mediators. METHODS: Immunofluorescence staining, reverse transcription-quantitative polymerase chain reaction, enzyme-linked immunosorbent assay (ELISA), and western blotting were used to assess Livin expression in patients with psoriasis, an imiquimod (IMQ)-induced psoriasis-like mouse model, and M5-treated HaCaT cells. To investigate the role of Livin in KCs, we performed RNA sequencing and proteomic analysis of Livin-knockdown (knockdown-HaCaT) and negative control (NC-HaCaT) cells. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes were used for enrichment analyses. Moreover, the effect of Livin expression on the release of inflammatory mediators in KCs was verified using ELISA. RESULTS: Livin expression was higher in KCs of patients with psoriasis than in those healthy controls. Livin expression in HaCaT cells treated with M5 increased significantly over time. Livin expression was higher in the skin lesions of the IMQ mouse model than in the control group. Proteomic analysis and RNA sequencing used to investigate the function of Livin in HaCaT cells revealed its potential role in mediating KC activation and inflammatory mediator release, which affected the pathology of psoriasis. CONCLUSIONS: Livin expression played an effect on KCs activation, which induced release of inflammatory mediators and up-regulation of keratin. This study provides a new effector molecule for the mechanism of inflammatory response in psoriasis.


Sujet(s)
Psoriasis , Maladies de la peau , Animaux , Humains , Souris , Prolifération cellulaire , Modèles animaux de maladie humaine , Imiquimod/effets indésirables , Imiquimod/métabolisme , Médiateurs de l'inflammation/effets indésirables , Médiateurs de l'inflammation/métabolisme , Kératinocytes/métabolisme , Protéomique , Psoriasis/anatomopathologie , Maladies de la peau/métabolisme
17.
Stem Cell Res Ther ; 15(1): 37, 2024 Feb 08.
Article de Anglais | MEDLINE | ID: mdl-38331803

RÉSUMÉ

Adipose-derived stem cells (ASCs) are a critical adult stem cell subpopulation and are widely utilized in the fields of regenerative medicine and stem cell research due to their abundance, ease of harvest, and low immunogenicity. ASCs, which are homologous with skin by nature, can treat immune-related skin diseases by promoting skin regeneration and conferring immunosuppressive effects, with the latter being the most important therapeutic mechanism. ASCs regulate the immune response by direct cell-cell communication with immune cells, such as T cells, macrophages, and B cells. In addition to cell-cell interactions, ASCs modulate the immune response indirectly by secreting cytokines, interleukins, growth factors, and extracellular vesicles. The immunomodulatory effects of ASCs have been exploited to treat many immune-related skin diseases with good therapeutic outcomes. This article reviews the mechanisms underlying the immunomodulatory effects of ASCs, as well as progress in research on immune-related skin diseases.


Sujet(s)
Cellules souches mésenchymateuses , Maladies de la peau , Adulte , Humains , Tissu adipeux , Cellules souches mésenchymateuses/métabolisme , Adipocytes , Peau , Maladies de la peau/thérapie , Maladies de la peau/métabolisme
18.
J Dermatol Sci ; 113(3): 93-102, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38383230

RÉSUMÉ

BACKGROUND: Aberrant keratinocytes differentiation has been demonstrated to be associated with a number of skin diseases. The roles of lncRNAs in keratinocytes differentiation remain to be largely unknown. OBJECTIVE: Here we aim to investigate the role of lnc-DC in regulating epidermal keratinocytes differentiation. METHODS: Expression of lnc-DC in the skin was queried in AnnoLnc and verified by FISH. The lncRNA expression profiles during keratinocytes differentiation were reanalyzed and verified by qPCR and FISH. Gene knock-down and over-expression were used to explore the role of lnc-DC in keratinocytes differentiation. The downstream target of lnc-DC was screened by whole transcriptome sequencing. CUT&RUN assay and siRNAs transfection was used to reveal the regulatory effect of GRHL3 on lnc-DC. The mechanism of lnc-DC regulating ZNF750 was revealed by RIP assay and RNA stability assay. RESULTS: Lnc-DC was biasedly expressed in skin and up-regulated during epidermal keratinocytes differentiation. Knockdown lnc-DC repressed epidermal keratinocytes differentiation while over-express lnc-DC showed the opposite effect. GRHL3, a well-known transcription factor regulating keratinocytes differentiation, could bind to the promoter of lnc-DC and regulate its expression. By whole transcriptome sequencing, we identified that ZNF750 was a downstream target of lnc-DC during keratinocytes differentiation. Mechanistically, lnc-DC interacted with RNA binding protein IGF2BP2 to stabilize ZNF750 mRNA and up- regulated its downstream targets TINCR and KLF4. CONCLUSION: Our study revealed the novel role of GRHL3/lnc-DC/ZNF750 axis in regulating epidermal keratinocytes differentiation, which may provide new therapeutic targets of aberrant keratinocytes differentiation related skin diseases.


Sujet(s)
ARN long non codant , Maladies de la peau , Humains , ARN long non codant/génétique , ARN long non codant/métabolisme , Facteurs de transcription/métabolisme , Kératinocytes/métabolisme , Peau/métabolisme , Maladies de la peau/métabolisme , Protéines de liaison à l'ADN/génétique , Protéines de liaison à l'ADN/métabolisme , Protéines de liaison à l'ARN/métabolisme , Protéines suppresseurs de tumeurs/métabolisme
20.
Int J Mol Sci ; 25(3)2024 Jan 30.
Article de Anglais | MEDLINE | ID: mdl-38338991

RÉSUMÉ

Side streams and byproducts of food are established sources of natural ingredients in cosmetics. In the present study, we obtained upcycled low-molecular-weight anionic peptides (LMAPs) using byproducts of the post-yuzu-juicing process by employing an enzyme derived from Bacillus sp. For the first time, we isolated anionic peptides less than 500 Da in molecular weight from Citrus junos TANAKA seeds via hydrolysis using this enzyme. The protective effect of LMAPs against UVR-induced photoaging was evaluated using a reconstructed skin tissue (RST) model and keratinocytes. The LMAPs protected the keratinocytes by scavenging intracellular reactive oxygen species and by reducing the levels of paracrine cytokines (IL-6 and TNF-α) in UVR (UVA 2 J/cm2 and UVB 15 mJ/cm2)-irradiated keratinocytes. Additionally, the increase in melanin synthesis and TRP-2 expression in RST caused by UVR was significantly inhibited by LMAP treatment. This treatment strongly induced the expression of filaggrin and laminin-5 in UVR-irradiated RST. It also increased type I collagen expression in the dermal region and in fibroblasts in vitro. These results suggest that a hydrolytic system using the enzyme derived from Bacillus sp. can be used for the commercial production of LMAPs from food byproducts and that these LMAPs can be effective ingredients for improving photoaging-induced skin diseases.


Sujet(s)
Citrus , Vieillissement de la peau , Maladies de la peau , Peau/métabolisme , Cytokines/métabolisme , Maladies de la peau/métabolisme , Rayons ultraviolets/effets indésirables , Fibroblastes/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...